| Literature DB >> 28900490 |
Jinming Xu1, Wang Lv1, Yeji Hu1, Luming Wang1, Yiqing Wang1, Jinlin Cao1, Jian Hu1.
Abstract
Background: Epithelial-mesenchymal transition (EMT) plays an important role in the invasion and migration during cancer metastasis. Wnt3a is one of the ligands in canonical Wnt/β-catenin signaling pathway, which contributes to the carcinogenesis and progression of lung cancer cell lines. The aim of this study was to evaluate the association between Wnt3a and EMT-related proteins (E-cadherin and N-cadherin), and to further investigate its impact on prognosis of lung adenocarcinoma patients.Entities:
Keywords: Wnt3a expression; lung adenocarcinoma
Year: 2017 PMID: 28900490 PMCID: PMC5595082 DOI: 10.7150/jca.18560
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Characteristics of subjects and Cox regression analyses of survival in lung adenocarcinoma patients.
| Factor | Category | Total | Event | Percent | Univariate HR | Multivariate HR | ||
|---|---|---|---|---|---|---|---|---|
| Wnt3a(C) | low | 109 | 52 | 47.71% | 1 | 1.000 | ||
| high | 38 | 27 | 71.05% | 2.214(1.386-3.536) | 0.001 | 1.285(0.756-2.184) | 0.355 | |
| Wnt3a(N) | low | 133 | 71 | 53.38% | 1 | |||
| high | 14 | 8 | 57.14% | 1.277(0.614-2.655) | 0.512 | |||
| E-cadherin(C) | low | 67 | 44 | 65.67% | 1 | 1.000 | ||
| high | 80 | 35 | 43.75% | 0.487(0.318-0.776) | 0.002 | 0.741(0.449-1.224) | 0.242 | |
| E-cadherin(N) | low | 35 | 17 | 48.57% | 1 | |||
| high | 112 | 62 | 55.36% | 1.138(0.665-1.947) | 0.638 | |||
| N-cadherin(C) | low | 82 | 29 | 35.37% | 1 | 1.000 | ||
| high | 65 | 50 | 76.92% | 3.246(2.046-5.150) | <0.001 | 1.984(1.164-3.381) | 0.012 | |
| N-cadherin(N) | low | 127 | 67 | 52.76% | 1 | |||
| high | 20 | 12 | 60.00% | 1.162(0.628-2.149) | 0.632 | |||
| Smoke | N | 82 | 45 | 54.88% | 1 | |||
| Y | 65 | 34 | 52.31% | 0.992(0.590-1.440) | 0.922 | |||
| Gender | F | 68 | 36 | 52.94% | 1 | |||
| M | 79 | 43 | 54.43% | 1.079(0.693-1.681) | 0.736 | |||
| Age* | <70 | 113 | 54 | 47.79% | 1 | 1.000 | ||
| ≥70 | 34 | 25 | 73.53% | 2.067(1.283-3.332) | 0.003 | 1.869(1.139-3.068) | 0.013 | |
| Pathological differentiation | poor | 46 | 25 | 54.35% | 1 | |||
| moderate and well | 101 | 54 | 53.47% | 0.884(0.550-1.421) | 0.611 | |||
| T stage | T1 | 32 | 10 | 31.25% | 1 | 1.000 | ||
| T2 | 83 | 47 | 56.63% | 2.120(1.070-4.201) | 0.031 | 1.487(0.708-3.125) | 0.295 | |
| T3-4 | 32 | 22 | 68.75% | 2.939(1.387-6.227) | 0.005 | 0.970(0.406-2.320) | 0.945 | |
| N stage | N0 | 80 | 25 | 31.25% | 1 | 1.000 | ||
| N1 | 31 | 22 | 70.97% | 2.803(1.577-4.983) | <0.001 | 2.522(1.366-4.656) | 0.003 | |
| N2 | 36 | 32 | 88.89% | 6.095(3.549-10.469) | <0.001 | 4.722(2.521-8.847) | <0.001 |
Univariate and multivariate analyses were conducted based on Cox regression model.
C: Primary lung adenocarcinoma cancerous tissues
N: Corresponding adjacent normal tissues
Figure 1Immunohistochemistry results of Wnt3a and EMT features in human lung adenocarcinoma tissue samples and prognostic Kaplan-Meier curves of Wnt3a. (A) sample I was representative NSCLC sample with Wnt3a high expression (A1), E-cadherin low expression (A3) and N-cadherin high expression (A5); sample II was representative lung adenocarcinoma sample with Wnt3a low expression (A2), E-cadherin high expression (A4) and N-cadherin low expression (A6) (200×magnification). (B) Kaplan-Meier curve for Wnt3a in lung adenocarcinoma patients, with Log Rank test P value 0.001. (C) Kaplan-Meier curve for E-cadherin in lung adenocarcinoma patients, with Log Rank test P value 0.002. (D) Kaplan-Meier curve for N-cadherin in lung adenocarcinoma patients, with Log Rank test P value <0.001.
Figure 2Kaplan-Meier curves of Wnt3a stratified by T stage and N stage. The prognostic value of Wnt3a was assessed in (A) stage T1-T2 patients (P=0.003), (B) stage T3-T4 patients (P=0.169), (C) stage N0 patients (P=0.031), and (D) stage N1-N2 patients (P=0.060).
The association between Wnt3a and EMT-related proteins (E-cadherin and N-cadherin) expression levels.
| Factors | Wnt3a expression level | |
|---|---|---|
| low (n=109) | high (n=38) | |
| E-cadherin expression | ||
| high (%) | 70 (64.22%) | 10 (26.32%) |
| low (%) | 39 (35.78%) | 28 (73.68%) |
| χ2 | 16.321 | |
| <0.001 | ||
| N-cadherin expression | ||
| high (%) | 35 (32.11%) | 30 (78.95%) |
| low (%) | 74 (67.89%) | 8 (21.05%) |
| χ2 | 25.060 | |
| <0.001 | ||
P-value was tested by Pearson Chi-square analysis
Figure 3A nomogram predicted survival risk based on Wnt3a, EMT-related proteins and other factors in patients with lung adenocarcinoma. (A) The nomogram created by R language with a C-index of 0.755. (B) The calibration curves for predicting patient survival at 3-year. (C) X-tile analysis of survival based on risk scores (cut off intervals: 1.54 to 12.50, 12.50 to 15.88 and 15.88 to 22.59). (D) Decision curve analysis of the nomogram. The net benefits (y axis) is plotted against the threshold probabilities of survival on the x axis (3-year survival probability of nomogram model and TNM model ranged from 21.6% to 82.0%, and from 31.8% to 71.0%, respectively).
Figure 4Wnt3a induced EMT and promoted in vitro invasion and migration abilities. (A) Wnt3a treatment (100ng/ml, 72 hours) could activate the classic Wnt/β-catenin signaling pathway by enhancing the expression of membrane receptor LRP6 and adaptor protein Dvl2 in HCC827 and PC9 cell lines (β-catenin (c): cytoplasm; β-catenin (n): nucleus). (B) Wnt3a treatment could induce mesenchymal phenotype and promote the EMT process. (C) Wnt3a treatment could promote in vitro migration and invasion abilities of HCC827 and PC9 cell lines.